Day: October 11, 2024

Company announcement no 16-2024 Søborg, October 16, 2024 Konsolidator completes private placement In company announcement no. 15-2024, Konsolidator A/S (“Konsolidator”) announced the resolution by the Board of Directors to issue up to 573,979 new shares in a private placement. The new shares have been subscribed for by existing investors. Konsolidator announces the completion of the private placement as all 573,979 new shares have been subscribed for and the total subscription amount of DKK 2.2m has been received by Konsolidator. The new shares and the related capital increase will be registered at the Danish Business Authority today, following which the company has a registered share capital of nominal DKK 909,388. The share capital will consist of 22,734,700 shares, each with a nominal value of DKK 0.04. Each share carries one vote,...

11 October 2024, 08:30 CET ArcelorMittal (the “Company”, “Group”) announces it has entered into a definitive Equity Purchase Agreement (the “Agreement”) with Nippon Steel Corporation (“NSC”) pursuant to which ArcelorMittal will purchase NSC’s 50% equity interest in the AM/NS Calvert Joint Venture (the “Transaction”). The Transaction has been entered in to at the request of NSC to address regulatory concerns pursuant to its agreed acquisition of US Steel. The Transaction is subject to NSC completing its pending acquisition of US Steel, which is subject to various other regulatory requirements. Under the terms of the agreement, ArcelorMittal will pay $1 consideration for the Transaction; further, NSC will inject cash and forgive partner loans in an amount estimated to be approximately $0.9 billion. There are no assurances or guarantees that...

Sanofi in discussions to sell a controlling stake in Opella Paris, October 11, 2024. Sanofi today announces that the company has entered into negotiations with CD&R for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. Should these discussions lead to a positive outcome, any agreement would be subject to the completion of the necessary social processes. Further updates on the potential separation of Opella will be provided in due course, when a decision is made. Headquartered in France, Opella employs over 11,000 people, operates in 100 countries, and manages 13 best-in-class manufacturing sites and four research and innovation centers. With a portfolio of 100 leading brands, including Allegra, Doliprane, Novanight, Icy Hot, and Dulcolax, Opella is the world’s third-largest company in...

For 2024, Jyske Bank expects a net profit of DKK 5.0bn-5.3bn, corresponding to earnings per share of DKK 75-80. Previously, guidance was for a net profit in the upper half of DKK 4.3bn-5.1bn and earnings per share in the upper half of DKK 64-76. Net profit amounted to slightly above DKK 1.4bn in the third quarter and slightly above DKK 4.0bn for Q1-Q3 2024. The upgrade follows favourable financial markets amid declining market rates that led to significant value adjustments in the third quarter. The credit quality remained solid and loan impairment charges amounted to an income in the quarter. Jyske Bank’s Interim Financial Report for the first nine months of 2024 is expected to be published on 29 October 2024. Yours faithfully, Jyske Bank Contact: Birger Krøgh Nielsen, CFO, tel. +45 89 89 64 44AttachmentCorporate Announcement...

        Pharma Equity Group announces successful completion of directed issue of new shares 11 October 2024Company Announcement no 26    With reference to company announcement no. 25 from 4. October 2024, Pharma Equity Group A/S (the “Company”) can hereby announce that the capital increase of a total nominal value DKK 20,459,277.6 corresponding to 204,592,776 new shares each with a nominal value of DKK 0.1 at a price of DKK 0.25 per share has been completed and the capital increase has been registered with the Danish Business Authority.   In accordance with section 32 of the Danish Capital Markets Act, the Company announces that after registration of the share capital increase, the Company’s share capital amounts to nominally DKK 122,755,665.9 divided into shares of DKK 0.1 each. The total number of voting...

In 2025, Arco Vara will release its consolidated financial reports on the following dates: 13.02.2025: Q4 2024 unaudited interim report03.04.2025: 2024 audited annual report24.04.2025: Q1 2025 unaudited interim report24.07.2025: Q2 2025 unaudited interim report23.10.2025: Q3 2025 unaudited interim report.Tiina Malm CFO Arco Vara AS Tel: +372 614 4630 tiina.malm@arcovara.com

THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO AUSTRALIA, CANADA, ITALY, DENMARK, JAPAN, THE UNITED STATES, OR TO ANY NATIONAL OF SUCH JURISDICTIONS NBPE Announces September Monthly NAV Estimate 11 October 2024 NB Private Equity Partners (NBPE), the $1.3bn1, FTSE 250, listed private equity investment company managed by Neuberger Berman, today announces its 30 September 2024 monthly NAV estimate. NAV Highlights (30 September 2024)NAV per share was $27.37 (£20.40), a total return of (0.3%) in the month Year to date NAV TR of 0.9% $73 million invested in new and follow on investments year to date $391 million of available liquidity at 30 September 2024As of 30 September 2024 YTD 1 Year 3 years 5 years 10 yearsNAV TR (USD)*Annualised 0.9% 4.3% (2.8%)(1.0%) 70.9% 11.3% 172.2%10.5%MSCI...

The number of digital subscriptions of AS Ekspress Grupp increased by 24% in the Baltic States year-over-year (3rd quarter: 0%, 9 months: 7%) and totalled 222 611 at the end of September.The number of digital subscriptions of AS Delfi Meedia that publishes the news portal Delfi, newspapers Eesti Päevaleht, Maaleht, Eesti Ekspress and several popular magazines increased by 14% year-over-year (3rd quarter: 5%, 9 months: 9%) and totalled 112 520. The number of digital subscriptions of AS Õhtuleht Kirjastus, 50% of which is owned by Ekspress Grupp, increased by 3% year-over-year (3rd quarter: -4%, 9 months: 5%) and totalled 26 127. The number of digital subscriptions of Geenius Meedia OÜ increased by 17% year-over-year (3rd quarter: 1%, 9 months: 8%) and totalled 7534. In Latvia, the number of digital subscriptions of Delfi A/S increased...

MEDIA RELEASEFirst FDA-approved abbreviated new drug application (ANDA) to reference medicine Single-dose 100 mg vial for intravenous use, approved for metastatic breast cancer Launch expected to be near-term growth driver in US marketPrinceton, NJ, October 11, 2024 – Sandoz, the global leader in generic and biosimilar medicines, today announced that it has launched a generic paclitaxel formulation in the US, the first generic to its reference medicine to be approved by the US Food and Drug Administration (FDA). Sandoz paclitaxel protein-bound particles for injectable suspension (albumin-bound) is indicated for the treatment of patients with metastatic breast cancer. The launch of the lyophilized powder for injection containing 100 mg of paclitaxel in a single-dose vial for intravenous use follows approval by the FDA on October 8,...